ARTV Insider Trading Activity and SEC Form 4 Filings
ARTV insider trading summary
Over the past 12 months, insiders at Artiva Biotherapeutics, Inc. (ARTV) reported 124 open-market purchases worth $589.1M by 8 insiders and 22 sales worth $2.6M by 5 insiders on SEC Form 4. Net insider buying was $586.5M.
Latest ARTV insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 2, 2026 | Fred Aslan | Chief Executive Officer | Sell | $260K (62,178 @ $4.18) |
| Nov 2, 2026 | Christopher Horan | Chief Tech Operations Officer | Sell | $44K (10,423 @ $4.18) |
| Nov 2, 2026 | Subhashis Banerjee | Chief Medical Officer | Sell | $5K (1,110 @ $4.18) |
| Nov 2, 2026 | Jennifer Bush | COO, CLO, Compliance Officer | Sell | $35K (8,439 @ $4.18) |
| Oct 6, 2026 | Fred Aslan | Chief Executive Officer | Sell | $169K (23,463 @ $7.20) |
| Oct 5, 2026 | Fred Aslan | Chief Executive Officer | Sell | $422K (61,696 @ $6.84) |
| Oct 5, 2026 | Jennifer Bush | COO, CLO, Compliance Officer | Sell | $57K (8,370 @ $6.84) |
| Oct 5, 2026 | Subhashis Banerjee | Chief Medical Officer | Sell | $8K (1,099 @ $6.84) |
| Oct 5, 2026 | Christopher Horan | Chief Tech Operations Officer | Sell | $71K (10,340 @ $6.84) |
| Sep 3, 2026 | Fred Aslan | Chief Executive Officer | Sell | $690K (61,888 @ $11.16) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.